Literature DB >> 16621522

Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.

Fernand Labrie1, Alain Bélanger, Patrick Bélanger, René Bérubé, Céline Martel, Leonello Cusan, José Gomez, Bernard Candas, Isabelle Castiel, Véronique Chaussade, Claire Deloche, Jacques Leclaire.   

Abstract

Despite the long series of cohort studies performed during the last 20 years, the correlation between serum testosterone and any clinical situation believed to be under androgen control in women has remained elusive. This is likely related to the recent finding that the androgens made locally in large amounts in peripheral tissues from the precursor dehydroepiandrosterone (DHEA) act in the same cells where synthesis takes place and are not released in significant amounts in the circulation, thus making unreliable the measurement of serum testosterone as marker of total androgenic activity. The objective is to determine if serum androgen glucuronides can be replaced by testosterone or another steroid as measure of androgenic activity. Since the glucuronide derivatives of androgens are the obligatory route of elimination of all androgens, these metabolites were measured by liquid chromatography tandem mass spectrometry under basal conditions in 377 healthy postmenopausal women aged 55-65 years as well as in 47 premenopausal women aged 30-35 years while testosterone was assayed by gas chromatography mass spectrometry. No correlation was found between the serum concentration of testosterone and that of androsterone glucuronide (ADT-G) or androstenediol glucuronide (3alpha-diol-G), the androgen metabolites which account for the total pool of androgens. The present data show that measurement of the total pool of androgens reflected by the serum levels of ADT-G and 3alpha-diol-G cannot be replaced by serum testosterone or any other steroid, including DHEA or DHEA sulphate. These findings may have implications for women with androgen deficiency involving osteoporosis, obesity, type 2 diabetes, sexual dysfunction, loss of muscular strength and a series of other clinical situations affecting women's health. Measuring ADT-G and 3alpha-diol-G might identify cases of true androgen deficiency and provide an opportunity to offer appropriate androgen therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621522     DOI: 10.1016/j.jsbmb.2006.02.004

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  53 in total

1.  Response to dr simes and dr snabes.

Authors:  Rosemary Basson
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

2.  Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Tania Processali; Marco Pirozzi; Aliasger Shakir; Nelia Amigoni; Riccardo Rizzetto; Matteo Brunelli; Filippo Migliorini; Salvatore Siracusano; Walter Artibani
Journal:  Int Urol Nephrol       Date:  2019-08-23       Impact factor: 2.370

3.  Bioactive androgens and glucuronidated androgen metabolites are associated with subcutaneous and ectopic skeletal muscle adiposity among older black men.

Authors:  Iva Miljkovic; Jane A Cauley; Amy S Dressen; Christopher L Gordon; Bret H Goodpaster; Lewis H Kuller; Clareann H Bunker; Alan L Patrick; Victor W Wheeler; Eric S Orwoll; Joseph M Zmuda
Journal:  Metabolism       Date:  2011-02-25       Impact factor: 8.694

4.  Sex steroids and bone health in older Chinese men.

Authors:  J Woo; T Kwok; J C S Leung; C Ohlsson; L Vandenput; P C Leung
Journal:  Osteoporos Int       Date:  2011-02-12       Impact factor: 4.507

5.  Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program.

Authors:  Catherine Kim; Shengchun Kong; Gail A Laughlin; Sherita H Golden; Kieren J Mather; Bin Nan; Sharon L Edelstein; John F Randolph; Fernand Labrie; Elizabeth Buschur; Elizabeth Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2012-06-11       Impact factor: 5.958

Review 6.  Progesterone and Breast Cancer.

Authors:  Britton Trabert; Mark E Sherman; Nagarajan Kannan; Frank Z Stanczyk
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 7.  Endogenous sex hormones, metabolic syndrome, and diabetes in men and women.

Authors:  Catherine Kim; Jeffrey B Halter
Journal:  Curr Cardiol Rep       Date:  2014-04       Impact factor: 2.931

8.  Gonadal sex steroid status and bone health in middle-aged and elderly European men.

Authors:  D Vanderschueren; S R Pye; K Venken; H Borghs; J Gaytant; I T Huhtaniemi; J E Adams; K A Ward; G Bartfai; F F Casanueva; J D Finn; G Forti; A Giwercman; T S Han; K Kula; F Labrie; M E J Lean; N Pendleton; M Punab; A J Silman; F C W Wu; T W O'Neill; S Boonen
Journal:  Osteoporos Int       Date:  2009-12-15       Impact factor: 4.507

9.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

10.  Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial.

Authors:  Julia Johansson; Leanne Redman; Paula P Veldhuis; Antonina Sazonova; Fernand Labrie; Göran Holm; Gudmundur Johannsson; Elisabet Stener-Victorin
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-03-12       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.